致幻剂辅助治疗：内科医生综述。

IF 3.4 4区医学 Q1 MEDICINE, GENERAL & INTERNAL

Cleveland Clinic Journal of Medicine Pub Date : 2025-03-03 DOI:10.3949/ccjm.92a.24032

Brian S Barnett, Erin E Mauney, Franklin King

{"title":"致幻剂辅助治疗：内科医生综述。","authors":"Brian S Barnett, Erin E Mauney, Franklin King","doi":"10.3949/ccjm.92a.24032","DOIUrl":null,"url":null,"abstract":"Preliminary evidence suggests that psychedelic-assisted therapy-the enhancement of psychotherapy with psychedelics such as 3,4-methylenedioxymethamphet-amine (MDMA) and psilocybin-may be efficacious for depression, posttraumatic stress disorder, substance use disorders, and other conditions. Therapeutic psychedelic research is advancing steadily, with psilocybin, MDMA, and lysergic acid diethylamide designated breakthrough therapies by the US Food and Drug Administration (FDA). However, in August 2024, the FDA declined to approve a New Drug Application for MDMA and asked its sponsor to conduct another phase 3 trial. Clinicians are urged to prepare for the possible return of psychedelics to medicine.","PeriodicalId":10245,"journal":{"name":"Cleveland Clinic Journal of Medicine","volume":"92 3","pages":"171-180"},"PeriodicalIF":3.4000,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Psychedelic-assisted therapy: An overview for the internist.\",\"authors\":\"Brian S Barnett, Erin E Mauney, Franklin King\",\"doi\":\"10.3949/ccjm.92a.24032\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Preliminary evidence suggests that psychedelic-assisted therapy-the enhancement of psychotherapy with psychedelics such as 3,4-methylenedioxymethamphet-amine (MDMA) and psilocybin-may be efficacious for depression, posttraumatic stress disorder, substance use disorders, and other conditions. Therapeutic psychedelic research is advancing steadily, with psilocybin, MDMA, and lysergic acid diethylamide designated breakthrough therapies by the US Food and Drug Administration (FDA). However, in August 2024, the FDA declined to approve a New Drug Application for MDMA and asked its sponsor to conduct another phase 3 trial. Clinicians are urged to prepare for the possible return of psychedelics to medicine.\",\"PeriodicalId\":10245,\"journal\":{\"name\":\"Cleveland Clinic Journal of Medicine\",\"volume\":\"92 3\",\"pages\":\"171-180\"},\"PeriodicalIF\":3.4000,\"publicationDate\":\"2025-03-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cleveland Clinic Journal of Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3949/ccjm.92a.24032\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cleveland Clinic Journal of Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3949/ccjm.92a.24032","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

摘要

初步证据表明，迷幻剂辅助疗法——用迷幻剂如3,4-亚甲基二氧甲基苯丙胺（MDMA）和裸盖菇素加强心理治疗——可能对抑郁症、创伤后应激障碍、物质使用障碍和其他疾病有效。治疗性迷幻药的研究正在稳步推进，裸盖菇素、MDMA和麦角酸二乙胺被美国食品和药物管理局（FDA）指定为突破性疗法。然而，在2024年8月，FDA拒绝批准MDMA的新药申请，并要求其赞助商进行另一项三期试验。人们敦促临床医生为致幻剂可能回归医学做好准备。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Psychedelic-assisted therapy: An overview for the internist.

Preliminary evidence suggests that psychedelic-assisted therapy-the enhancement of psychotherapy with psychedelics such as 3,4-methylenedioxymethamphet-amine (MDMA) and psilocybin-may be efficacious for depression, posttraumatic stress disorder, substance use disorders, and other conditions. Therapeutic psychedelic research is advancing steadily, with psilocybin, MDMA, and lysergic acid diethylamide designated breakthrough therapies by the US Food and Drug Administration (FDA). However, in August 2024, the FDA declined to approve a New Drug Application for MDMA and asked its sponsor to conduct another phase 3 trial. Clinicians are urged to prepare for the possible return of psychedelics to medicine.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Cleveland Clinic Journal of Medicine 医学-医学：内科

CiteScore

3.80

自引率

0.00%

发文量

109

审稿时长

6-12 weeks

期刊介绍： The mission of Cleveland Clinic Journal of Medicine (CCJM) is to provide its readers with up-to-date, practical, clinical information relevant to internal medicine, cardiology, and related fields. Consistent with this mission, CCJM focuses on timely review articles and other content that has a continuing-education orientation rather than on original research or case reports. CCJM authors, drawn from Cleveland Clinic and other top medical institutions throughout the world, are asked to identify new findings that are changing the practice of medicine and to advise readers how to apply them in daily patient care. Authors are chosen for their experience, acquired through caring for patients, teaching other physicians, and researching clinical questions.